Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases, thereby extending its spectrum of activity.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia
* Febrile neutropenia (in combination with an aminoglycoside)
## Adult Dosing
* **Complicated Intra-abdominal Infections, Complicated Skin and Skin Structure Infections, Community-Acquired Pneumonia:** 3.375 grams every 6 hours or 4.5 grams every 8 hours intravenously (IV).
* **Hospital-Acquired Pneumonia:** 4.5 grams every 6 hours intravenously (IV). Duration is typically 7 days.
* **Febrile Neutropenia:** 4.5 grams every 6 hours intravenously (IV), often combined with an aminoglycoside. Duration is guided by clinical response and resolution of neutropenia.
Dosing frequency and duration are dependent on the severity of infection and clinical response. Local protocols may guide specific dosing regimens.
## Pediatric Dosing
* **Children 2 months and older:** Dosing is based on piperacillin component:
* **Intra-abdominal infections, Skin and skin structure infections:** 90-100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 6 hours.
* **Hospital-acquired pneumonia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 6 hours.
* **Febrile neutropenia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 6 hours, often with an aminoglycoside.
Maximum dose generally should not exceed the adult dose of 4.5 grams per dose.
## Dose Adjustments
* **Renal Impairment (CrCl ≤ 40 mL/min):** Reduce dose frequency.
* 3.375 g every 8 hours IV
* 4.5 g every 8 hours IV
* (Specific adjustments for pediatric patients should be made in consultation with renal function guidelines.)
* **Hepatic Impairment:** No specific dose adjustment.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam therapy.
## Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, injection site reaction.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), interstitial nephritis, hematologic changes (e.g., leukopenia, thrombocytopenia, eosinophilia), liver enzyme elevations.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin serum concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease INR. Monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate levels. Monitor methotrexate levels.
## Monitoring
* Renal function (especially in patients with pre-existing renal impairment or receiving concurrent nephrotoxic agents).
* Liver function tests.
* Complete blood count (CBC) with differential and platelet count.
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *Clostridioides difficile*-associated diarrhea.
* Prothrombin time/INR if on warfarin.
* Methotrexate levels if co-administered.
## Clinical Pearls
* Piperacillin-tazobactam is often reserved for more serious infections due to its broad spectrum and potential for resistance development.
* Ensure adequate hydration and correct dilution for IV administration to minimize infusion-related reactions.
* If a hypersensitivity reaction occurs, discontinue immediately and manage appropriately.
* Consider de-escalation to a narrower-spectrum agent once culture and sensitivity results are available and the patient is improving.
* The risk of seizures is increased with high doses and impaired renal function.
***
*Disclaimer: This information is intended for clinical decision support and does not replace comprehensive drug information resources or institutional guidelines. Always verify current prescribing information with the manufacturer's package insert and institutional protocols.*
